The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background/Rationale: Alzheimer’s disease (AD) represents a serious public health issue affecting approximately 5.4 million individuals in the United States and is projected to affect up to 16 million by 2050. This study examined health care resource utilization (HCRU), costs, and comorbidity burden immediately preceding new diagnosis of AD and 2 years after diagnosis. Methods: This study utilized a claims-based, retrospective cohort design. Medicare Advantage members newly diagnosed with AD (n = 3374) were compared to matched non-AD controls (n = 6748). All patients with AD were required to have 12 months of continuous enrollment prior to AD diagnosis (International Classification of Diseases, Clinical Modification [ICD-9] 331.0), during which time no diagnosis of AD, a related dementia, or an AD medication was observed. Non-AD controls demonstrated no diagnosis of AD, a related dementia, or a prescription claim for an AD medication treatment during their health plan enrollment. Medical and pharmacy claims data were used to measure HCRU, costs, and comorbidity burden over a period of 36 months (12 months pre-diagnosis and 24 months post-diagnosis). Results: The HCRU and costs were greater for AD members during the year prior to diagnosis and during postdiagnosis years 1 and 2 compared to controls. The AD members also displayed greater comorbidity than their non-AD counterparts during postdiagnosis years 1 and 2, as measured by 2 different comorbidity indices. Conclusions: Members newly diagnosed with AD demonstrated greater HCRU, health care costs, and comorbidity burden compared to matched non-AD controls.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several groups of researchers have found that both health care and prescription drug spending are significantly higher in the year prior to diagnosis, 733-735 two years prior to diagnosis 736 and one year after diagnosis, 718,733,734 compared with otherwise similar individuals not diagnosed with Alzheimer's or another dementia, although the sources of increased spending differ across these studies”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [733]
In the citing paper
“Several groups of researchers have found that both health care and prescription drug spending are significantly higher for people diagnosed with Alzheimer's or other dementias in the year prior to diagnosis, 879 , 880 , 881 although the sources of increased spending differed across these studies.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [879]
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“Deyo-Charlson Comorbidity Index (DCI) scores were determined based on the diagnostic codes associated with medical claims.(15) The Deyo implementation of the Charlson Comorbidity Index consists of identifying 17 disease state categories based on the ICD-9 codes, and the index score is determined based on weighting the…”
MethodSmearing Estimate: A Nonparametric Retransformation Method
Duan, N. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10478017 · Cited by 2,232
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis
Bäckman, L., Jones, S., Berger, A.-K., Laukka, E. J., & Small, B. J. (2005) · Neuropsychology · doi:10.1037/0894-4105.19.4.520 · Cited by 735
Dementia associated with Parkinson's disease
Emre, M. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00351-x · Cited by 685
Neuropsychological detection and characterization of preclinical Alzheimer’s disease
Jacobs, D. M., Sano, M., Dooneief, G., Marder, K., Bell, K. L., & Stern, Y. (1995) · Neurology · doi:10.1212/wnl.45.5.957 · Cited by 409
Bynum, J. P. W., Rabins, P. V., Weller, W., Niefeld, M., Anderson, G. F., & Wu, A. W. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52054.x · Cited by 405
The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease
Rosenberg, P. B., Mielke, M. M., Appleby, B. S., Oh, E. S., Geda, Y. E., & Lyketsos, C. G. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.01.006 · Cited by 366
Small, B. J., Fratiglioni, L., Viitanen, M., Winblad, B., & Bäckman, L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.839 · Cited by 329
Motor Dysfunction in Mild Cognitive Impairment and the Risk of Incident Alzheimer Disease
Aggarwal, N. T., Wilson, R. S., Beck, T. L., Bienias, J. L., & Bennett, D. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1763 · Cited by 306
Research works printed but not linked: 4
- Menzin J, 1999, Am J Geriatr Psychiatry, 7, 300
- Linkins K, 2000, Drug Benefit Trends, 12, 6
- Fillit H, 2002, Fam Med, 34, 528
- Farley JF, 2006, Am J Manag Care, 12, 110
Cited by
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Metadata
- Authors
- Suehs, B. T., Davis, C. D., Alvir, J., van Amerongen, D., PharmD, N. C. P., Joshi, A. V., Faison, W. E., & Shah, S. N.
- Affiliations
- Competitive Health Analytics, Inc, Louisville, KY, USA
- Pfizer (United States) (US)
- Humana, Inc, Cincinnati, OH, USA
- Corresponding author
- Suehs, Brandon T.
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2013-05-17
- Volume
- 28
- Issue
- 4
- Pages
- 384-392
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- PMC
- PMC10852751
- OpenAlex
- W2314796676
- Cited by
- 71
- References
- 38
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 7
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, Medicare Advantage, healthcare resource utilization, health care costs, comorbidity burden, comorbidity index, dementia, economic burden, clinical burden
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Health Expenditures, Female, Health Services, Humans, Insurance Claim Review, Longitudinal Studies, Male, Retrospective Studies, United States, Comorbidity, Health Care Costs, Cost of Illness, Medicare Part C
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population. https://app.cochat.ai/papers/10.1177/1533317513488911
- The paper
- Suehs, B. T., Davis, C. D., Alvir, J., van Amerongen, D., PharmD, N. C. P., Joshi, A. V., Faison, W. E., & Shah, S. N. (2013). The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317513488911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.